Table III.

Management of ocular events in the dermatology clinic

Recommendation	Level of consensus
Appropriate treatments for conjunctivitis include: lubricating eye drops antihistamine/mast cell stabilizers corticosteroid eye drops	Agreed: 76% (vote 1)
The timescale for treatment is 2 weeks. If there is no improvement, refer to an ophthalmologist.
Appropriate treatments for mild blepharitis include: lubricating eye drops antihistamine/mast cell stabilizers topical calcineurin inhibitors/topical corticosteroids on the eyelids	Agreed: 94% (vote 1)
The timescale for treatment is 2 weeks. If there is no improvement, refer to an ophthalmologist.
Appropriate treatments for eyelid eczema include: topical calcineurin inhibitors/topical corticosteroids on the eyelids emollient cream	Agreed: 100% (vote 1)
Consider ways of enhancing local communication between dermatologists and ophthalmologists for patients with ocular manifestations of AD or medication-induced ocular events.	Agreed: 100% (vote 1)
Before starting treatment with dupilumab, dermatologists should assess patients' ocular histories.	Agreed: 100% (vote 1)
Before starting treatment with dupilumab, dermatologists should inform patients of the risk of ocular manifestations associated with dupilumab.	Agreed: 100% (vote 1)
Before starting treatment with dupilumab, dermatologists should inform patients of the possible benefits of the early use of preservative-free lubricating eye drops 3–5 times per day.	Agreed: 94% (vote 1)
Dermatologists should manage adverse events associated with dupilumab in the same way they manage the other ocular manifestations of AD. However, dermatologists should be extra vigilant with conjunctivitis, blepharitis and redness, and have a lower threshold for referral in patients exhibiting these conditions and signs.	Agreed: 82% (vote 1)

AD: atopic dermatitis; Agreed: “strongly agree” + “agree” votes.